Status:
UNKNOWN
The 90% Effective Sedation Dose Of Midazolam
Lead Sponsor:
King Fahad Specialist Hospital Dammam
Conditions:
Gastro-Esophageal Reflux Disease With Ulceration
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
There are no clear conclusive clinical reports defining the adequate effective dose of midazolam in patients undergoing day-case esophageal-gastro-duodenoscopy (EGD). Defining such dosage will facilit...
Detailed Description
Midazolam is widely used in conscious sedation during esophageal-gastro-duodenoscopy (EGD) to increase patient's tolerance and cooperation. Its short duration, cardiorespiratory stability, anxiolytic ...
Eligibility Criteria
Inclusion
- ASA 1\&2
Exclusion
- Patients with hypersensitivity to midazolam,
- Age less than 18,
- Obstructive sleep apnea
- known or suspected memory impairment,
- Patients with psychiatric disorders,
- visual or hearing impairment and pregnancy
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03813043
Start Date
February 15 2019
End Date
December 15 2019
Last Update
January 23 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.